Applications

G4 has been designed to deliver fast, flexible sequencing for a range of genomic applications. Explore the data and performance for your applications.

Unmatched Versatility Serving a Broad Range of Applications

Icon Bolt

1.6 Billion Paired Reads
up to480 Gb

Icon Speed

<24 Hour Run Times

Icon Split

1-4 Flow Cells
4-16 Lanes

Explore your Applications

RNA Sequencing

RNA sequencing (RNA-Seq) is used to assess differential gene expression profiles, detect novel transcripts, and characterize new splice variants or cell types. Explore how the reimagined chemistry and advanced engineering of G4 can improve your RNA sequencing.  

F2 Flow Cell
Samples / Flow Cell
F3 Flow Cell
Samples / Flow Cell
Samples / Run
4 8 32

(2×100 bp, 50M paired reads)

Single Cell RNA Sequencing

Single cell RNA sequencing (scRNA-Seq) has revolutionized basic and translational research in immunology, developmental biology and cancer by enabling the resolution of distinct cell populations within heterogeneous samples. Explore how G4 can seamlessly integrate into your scRNA-Seq workflow and accelerate your results without sacrificing accuracy.

F2 Flow Cell
Samples / Flow Cell
F3 Flow Cell
Samples / Flow Cell
Max Read
Samples / Flow Cell
Samples / Run
1 2 4 16

(28×91 configuration, 10,000 cells/sample and 20,000 paired reads/cell)

Whole Exome Sequencing

Whole exome sequencing (WES) is a next-generation sequencing method used to discover and assess genetic variations linked to rare or complex diseases. Learn how G4 provides excellent variant-calling accuracy and unmatched speed and versatility to labs performing WES.

F2 Flow Cell
Samples / Flow Cell
F3 Flow Cell
Samples / Flow Cell
Samples / Run
17 35 141

(2×150 bp, 34 Mb at 100x coverage)

Whole Genome Sequencing

Whole genome sequencing (WGS) is the process for analyzing the complete genetic makeup of an organism. Learn more about the suitability of G4 for human whole genome sequencing in the WGS technical report.

F2 Flow Cell
Samples / Flow Cell
F3 Flow Cell
Samples / Flow Cell
Samples / Run
1 4

(2×150 bp, 3 Gb at 30x coverage)

Metagenome Sequencing

Metagenomic next-generation sequencing (mNGS), also known as shotgun sequencing, is considered a “hypothesis-free” approach that enables researchers to identify potential pathogens in a heterogeneous mixture of microbes, through a sensitive and unbiased method. Explore how G4 performance and run flexibility are accelerating research for labs running metagenome sequencing.

F2 Flow Cell
Samples / Flow Cell
F3 Flow Cell
Samples / Flow Cell
Samples / Run
20 40 160

(2×150 bp, 10M paired reads)

Innovation with Intention

Featuring novel, high-performance chemistry and advanced engineering, the G4 Sequencing Platform has been optimized to deliver speed, power, unprecedented flexibility, and accuracy.

Download RNA-Seq App Note

Please take a moment to provide some information prior to downloading the RNA-Seq App note.

Download Single Cell RNA-Seq Application Note

Please provide your information to download the app note.

Download Whole Exome Sequencing App Note

Please provide your information to download the exome sequencing app note.

Download WGS Tech Report

Explore and download the G4 Sequencer’s coverage, quality, accuracy and variant calling performance for Whole Genome Sequencing.

Download Poster

Please take a moment to provide some information prior to downloading.

 

Drew Spaventa

Drew founded Singular Genomics in 2016 serving as the CEO and Chairman. Drew is a serial entrepreneur and venture investor in the biotech industry and has been involved in the founding of several successful companies. Prior to Singular Genomics, Drew founded Truvian Sciences, a low volume blood testing technology aimed at making routine blood tests easier, less invasive, and more affordable. Drew was also involved in the founding of Aspen Neurosciences where he co-led the seed financing and helped assemble a world-class team to combat Parkinson’s Disease using a patient’s own stem cells. Drew was also a seed investor and held an operating role in Edico Genome which sold to Illumina in 2018.

Drew received an MBA from the Rady School of Management at the University of California, San Diego and a BA in Political Science and International Relations from the University of California, San Diego.

Max Reads Application Note